introduction mitochondrial disease group complex inborn metabolic defect caused mutation nuclear dna ndna mitochondrial dna mtdna prevalence approximately 5,000 carrier rate approximately individual general mitochondrial disorder paediatric patient mainly caused nuclear-encoded gene severe manifestation majority protein subunit protein maintain mitochondrial structure function encoded approximately nuclear gene moreover expression mtdna gene regulated ndna ndna variant could exacerbate mtdna variant resulting multiple deletion mtdna mostly seen adult addition even typical phenotype leigh syndrome identifiable neuroimaging could caused numerous ndna mtdna variant overall relationship ndna mtdna extremely complicated ndna mtdna variant difficult distinguished based clinical data due clinically genetically heterogeneous feature selection genomic test interpretation variant still challenging respiratory chain enzyme activity assay muscle biopsy skin fibroblast widely used diagnosis however biopsy invasive method acceptable parent paediatric patient therefore diagnosis process genotype first become popular forny recommended histological testing case critical illness confirm pathogenicity variant unknown significance clinical wherein molecular diagnosis negative remained highly suspicious development high-throughput sequencing technology decreasing cost whole-exome sequencing mtdna sequencing convenient molecular diagnosis non-invasive bigenomic sequencing approach comprising whole exome mtdna sequencing recommended first step identifying study retrospectively evaluated criterion mdc molecular diagnostic yield dual genomic sequencing unrelated paediatric patient hospital aiming summarize efficiency dual genomic sequencing propose future direction diagnostic approach material method patient cohort total paediatric patient undergoing dual genomic analysis enrolled nine hospital belonging mitochondrial consortium unit january march patient unexplained neuromuscular system multisystem progressive disorder suspected mitochondrial disorder clinical data patient including phenotypic information neuroimaging routine biochemical test result mdc score retrospectively analysed assessed molecular diagnosis based whether variant explained clinical feature clinical matching patient previously reported one combining american college medical genetics acmg classification variant segregation pattern gene classified mitochondria-related associated documented literature non-mitochondria-related case mtdna sequencing peripheral blood sample collected 3–5 dna extracted using salt extraction method dna extraction kit according manufacturer instruction mike bio china mitochondrial amplification performed using mitochondria-specific primer thereafter ultrasonic method used disrupt mitochondrial amplification product mitochondrial library established using kapa htp library preparation kit kapa biosystems inc. woburn usa high-throughput sequencing performed using nextseq sequencer illumina san diego usa average sequencing depth supplementary table collecting data bioinformatic analysis gene sequence performed confirm locus pathogenic gene mtdna variant classified according mrna trna variant classification criterion ndna sequencing genomic dna extracted whole blood patient parent sequenced using illumina hiseq sequencer illumina novaseq platform least q20 base quality mean nuclear coverage supplementary table sequence compared human reference genome using nextgene software softgenetics state college usa true false variant identification single-nucleotide variant retained annotated filtering high-frequency variant using population frequency dbsnp exac gnomad literature database omim hgmd clinvar mastermind multiple software sift polyphen2 mutationtaster alamutvisual used predict pathogenicity based amino acid conservation evolutionary prediction splicing site effect variant confirmed sanger sequencing classified according acmg genomics guideline cnv-sequencing experimental analytical method performed previously described genomic dna extracted followed random fragmentation short-read sequencing using illumina nextseq500 novaseq6000 sequencer illumina san diego usa resolution sequencing read cleaned removing read base quality q20 mapped reference human genome version grch38/hg38 high-variation region indicating highly homologous repeated region across different sample excluded analysis interpretation copy number variation cnvs based acmg clingen data analysis statistic statistical analysis performed using graphpad prism 8.0 software san diego usa statistically significant difference group analyzed using one-way anova statistical significance defined 0.05 0.005 0.001 0.0001 ethic approval consent participate////// ethical approval study obtained xiangya hospital ethic committee written informed consent obtained participant parent legal guardian participant age method performed accordance relevant guideline regulation consent publication study doe include personal information leading identification participant result dual genome test result among patient mitochondria-related variant identified 8.5 table addition patient presented variant ndna-encoded gene mtdna variant six harboured mitochondria-related ndna mtdna variant nuclear-encoded gene included polg gtpbp3 etfdh3 hibch aars2 acad9 aifm1 cars2 coq4 dnm1l gfm1 hsd17b10 lipt1 naxe opa3 ndufaf5 pank2 pdhb twnk wars2 pdha1 furthermore mtdna gene included mt-tl1 mt-atp6 mt-nd1 mt-nd3 mt-nd4 mt-co2 deletion m.10947-15362del four patient harboured dual genomic variant related mitochondrion fig mt-nd6 polg mt-nd5 rars2 tl1 nars2 mt-co2 ndufs1 two patient presented mtdna non-mitochondria-related ndna variant fig mt-cyb marca2 chrna4 mt-co3 table summary clinical feature patient mtdna or/and ndna variant full size table figure family pedigree six patient dual genomic variant full size image patient 26.0 found non-mitochondria-related variant including patient pathogenic cnvs supplementary table dual genomic analysis failed identify definitive causative variant patient 64.8 patient harboured low level heteroplasmic mtdna variant blood m.4358g 8.60 m.10437g blood 3.00 urine m.594insc 21.80 m.15867a 9.20 m.5703g 2.50 m.3250 6.60 variant uncertain significance pmp22 c.235 infantile spasm kcnh5 c.976g epilepsy sema3e plec suspected patient demographic clinical presentation male preponderance boy 59.4 girl 40.6 included male female ratio 2.75 observed patient mtdna variant table median age onset 6.3 year range 0.5–14 year patient mtdna variant one year range 0–13 year mitochondria-related ndna variant patient non-mitochondria-related variant median 0.5 year negative genetic test median one year even younger age first presentation mtdna defect first symptom included seizure developmental delay regression muscle weakness failure thrive ptosis vomiting increased alanine transaminase/aspartate transaminase ataxia headache visual sign seizure developmental delay two common symptom mitochondrial non-mitochondrial patient cohort table summary demographic clinical presentation study full size table serum lactate level patient mtdna mitochondria-related ndna dual genomic variant 5.0 2.0 mmol/l 5.7 5.4 mmol/l 4.4 2.5 mmol/l respectively patient non-mitochondria-related variant negative genetic test showed lower lactate level 3.3 3.28 mmol/l 2.80 2.02 mmol/l respectively table compared patient negative genetic result mtdna 0.0076 mitochondria-related ndna 0.0483 variant showed significantly higher lactate level addition patient mitochondria-related ndna variant significantly higher lactate level non-mitochondria-related ndna variant 0.0076 neuroimaging data available patient exhibited normal brain magnetic resonance imaging mri finding frequent neuroradiological presentation included white matter 14.0 basal ganglion 9.2 cortical abnormality 6.1 cerebral atrophy 5.6 cerebellar atrophy 3.9 corpus callosum 3.6 brainstem thalamic 2.9 involvement common presentation include optic atrophy ventriculomegaly cyst basal ganglion characteristic observed mitochondrial patient 32.6 mitochondrial disease criterion according mdc 15.2 52.2 32.6 patient mtdna mitochondria-related ndna variant classified unlikely mitochondrial disorder score possibly mitochondrial disorder score probably mitochondrial disorder score respectively fig comparison mdc score mtdna mitochondria-related ndna variant shown fig 42.6 18.7 patient whose causative variant detected determined unlikely mitochondrial disorder possibly mitochondrial disorder patient non-mitochondria-related variant corresponding percentage 39.0 39.0 confirmed mitochondrial case low mdc score due organ-specific presentation leber hereditary optic neuropathy lhon progressive external ophthalmoplegia cerebellar ataxia single clinical symptom epileptic encephalopathy without characteristic mri lactate level finding importance part might missed low score noted figure percentage distribution different group referring mdc score left comparison three group including negative mitochondria-related non-mitochondria-related ndna variant right comparison mtdna mitochondria-related ndna variant full size image addition noteworthy gene patient high mdc score case non-mitochondria-related variant evaluated probably mitochondrial disorder variant mmachc mcee folr1 g6pc gene grouped causative gene metabolic disease affecting multiple system case high mdc score confirmed causative variant could detected require study eight-year-old girl presenting developmental delay vomiting abnormal behaviour whose examination showed hypoglycaemia high serum lactate 5.04 mmol/l bilateral basal ganglion involvement novo variant c.760g p.e254q sema3e gene identified girl ventricular sepal defect presented seizure fever examination showed 5833u/l ckmb 369.9u/l ldh 1876u/l bilateral basal ganglion involvement brain mri however mitochondria-related variant plec gene c.10947c p.f3649l c.7603c p.r2535c identified discussion two-step next-generation sequencing approach patient evaluated based whole exome sequencing excluding pathogenic variant mtdna frequently used previous cohort simultaneous sequencing dual genome including mtdna genome-wide sequencing combined whole-exon sequencing trio common paediatric cohort recently whole-genome sequencing used determine gene-disease association dual genomic sequencing choice widespread use whole genome sequencing helpful comprehensive diagnosis establishment mitochondrial disease knowledge base child mainly caused ndna variation accounting 75–95 china mtdna variation accounted main part child previous study addition similar proportion found previous local cohort explanation might selection bias detection method limitation targeted gene panel sequencing previous year conditional mitochondrial encephalomyopathy lactate acidosis stroke-like episode melas lhon relatively easy catch attention physician targeted gene panel mtdna hotspot test unlikely detect novel gene variant study dual genomic sequencing provided accurate data ndna variant 25/46 accounted larger proportion mtdna variant 15/46 describe finding routine diagnostic ndna sequencing combined mtdna genome-wide sequencing patient suspected overall molecular diagnosis established patient 34.5 cohort similar finding previous study stringent inclusion criterion similarly participant suspected year old received molecular diagnosis using whole genome sequencing previous study 5.3 37.2 16.8 patient suspected identified mtdna mitochondria-related ndna non-mitochondria-related ndna variant respectively patient molecular diagnosis lower percentage mitochondria-related higher percentage non-mitochondria-related variant detected cohort ratio similar previous study wherein 28/75 patient definite diagnosis gene known cause primary mitochondrial disease including four mtdna variant diagnosis nuclear-mitochondrial gene whereas 47/75 non-mitochondrial gene precise comparison overall diagnostic rate previous study difficult given existence several bias affect diagnostic rate including prior mtdna/ndna genetic screening population characteristic phenotyping accuracy cohort consists patient nine hospital clinical suspicion mitochondrial disease patient varied relatively low high therefore cohort represents heterogeneous group suspected mitochondrial patient first foremost retrospective cohort study possible control factor led selection certain genetic testing method diagnostic rate varied depending presenting clinical phenotype highest diagnostic rate achieved patient suspected presented clear clinical phenotype well known percentage detected md-related gene could increase increased mdc score limited diagnostic rate could associated relative low mdc score cohort since diagnosis process genotype first performed widely lacking biochemical histopathological support median age onset 0.9 0–13 year cohort genetic test performed rapidly broadly infant child suspected hereditary disease non-mitochondrial disorder common mitochondrial disorder feature resembling mitochondrial disease often referred phenocopies could broadly classified developmental disorder intellectual disability metabolic disorder myopathy cardiomyopathy epileptic encephalopathy leukodystrophies ciliopathies amyloidosis neurogenetic disorder including basal ganglion calcification neurodegeneration iron accumulation mdc system built summarising known typical guiding selection diagnostic method high mdc score hallmark diagnosis similarly study correlation degree diagnosis mdc score moreover growing number new ndna mtdna variant found patient atypical clinical presentation isolated symptom developmental neurological metabolic abnormality common manifestation metabolic disease leading high mdc score cohort diagnosis non-mitochondrial disorder including developmental disorder epilepsy myopathy multisystem disorder previous study patient probable definite mitochondrial disorder according modified mdc score non-mitochondrial disorder regarding mimic combination ndna mtdna sequencing able detect variant comprehensive perspective thereby allowing diagnosis differentiation patient treatable condition enabling appropriate care treatment respective disease ruling observed cohort methylmalonic acidemia mmachc mcee glycogen storage disease g6pc cerebral folate deficiency folr1 many overlapping feature sequencing cost decreased genetic sequencing became readily available genetic test acceptable invasive muscle biopsy genetic test giving direction genetic metabolic disease could confirmed diagnostic test gas chromatography mass spectrometry liquid chromatography-tandem mass spectrometry sema3e plec identified two patient high mdc score based existing research two gene could completely account symptom observed two patient mtdna variant older age onset higher lactate level cohort however definite guideline selection genomic test distribution mdc score mtdna mitochondria-related ndna variant significantly different selecting mtdna ndna sequence based clinical feature mdc score difficult regarding patient dual genomic variant selecting candidate variant interpreting disease-causing role even challenging nuclear-mitochondrial intergenomic communication disorder result loss instability mitochondrial genome turn impaired maintenance qualitative quantitative mtdna integrity mn1 patient mdc dual genomic variant nd6 m.14453a 69.1 polg c.3643 tested dna polymerase error prominent role mtdna mutation arising spontaneous error dna replication unrepaired damage mtdna introduces miscoding lesion already known polg gene responsible replication mtdna could lead depletion mtdna and/or accumulation multiple mtdna deletion mouse model polg mutation frequency mutation found 500-fold higher heterozygous mouse 2,500-fold higher homozygous mouse aged wild-type mouse however regarding patient c.3643 reported trans another pathogenic variant child alpers syndrome therefore c.3643 suspected autosomal recessive inheritance since m.14453a heteroplasmy 69.1 reported cause melas classified pathogenic mtdna variant might considered finally responsibe patient guan identified mutant cell line harbouring m.7511a yars2 mutation exhibited greater deficiency mitochondrial function overexpression hars2 cytoplasmic hybrid cell carrying m.12201 mutation reversed mitochondrial dysfunction possible interaction occurred ndna mtdna variant rather simple single-gene disorder since nars2 rars2 hars2 ears2 belong large gene family aminoacyl trna synthetases function translation mtdna although tried analyse major causative gene mtdna ndna case still ambiguous nars2 mt-tl1 m.3243a mn3 patient mdc m.3243a reported patient higher heteroplasmy level point mutation exhibit mitochondrial encephalomyopathy lactic acidosis stroke-like episode melas low heteroplasmy level mainly maternally inherited diabetes deafness midd study conducted long-term hearing evaluation patient melas midd harbored m.3243a mutation mitochondrial dna identified age onset hearing loss correlated heteroplasmy mean age onset hearing loss 28.6 year however hearing loss occurred earlly patient treated cochlear implantation three year old mutation nars2 associated combined oxidative phosphorylation deficiency autosomal recessive deafness seizure hearing impairment common clinical finding nars2 patient previous study reported patient novel nars2 variant causing infantile-onset severe epilepsy patient continuous bilateral clonic myoclonic seizure paroxysmal episode upward eye deviation normal serum csf lactate level initially brain mri normal repeated imaging showed progressive cortical periventricular brain atrophy however finsterer commented investigation mdna performed tell nars2 variant altered mtdna sequence resulted mtdna depletion observed patient developmental regression seizure hearing loss could explaind perfectly nars2 variant however investigation mdna found another variant m.3243a observed mother could tell m.3243a caused nars2 variant clinical manifestation attributed m.3243a mn2 patient mdc harboured nd5 m.13327a 60.60 rars2 c.1210a c.622c however m.13327a interpretated benign variant based modified acmg guideline bs1 bs4 rars2 likely cause early onset epileptic encephalopathy patient similarly mn4 patient mdc harbored mtdna variant m.7979g two variant ndufs1 c.1222c c.61 3_61 6delgagt m.7979g located mt-co2 encoding subunit complex ndufs1 encodes fe-s protein operating within complex variant mt-co2 ndufs1 associated leigh syndrome clinical manifestation muscle weakness growth restriction brain mri basal ganglion brainstem involvement explained two gene overlapping effect could comfirmed ndufs1 assessed major pathogenic variant however m.7979g noval variant fully ruled though low-level heteroplasmy regard two patient mtdna non-mitochondria-related ndna variant judging whether could diagnosed difficult patient mt-cyb m.15272a 17.8 novo smarca2 c.1399c variant presented psychomotor regression seizure dysarthria high serum lactate 6.81 mmol/l although patient auricular deformity lacked distinctive facial appearance nicolaides-baraitser syndrome blepharophimosis-impaired intellectual development syndrome caused smarca2 variant m.15272a reclassified uncertain significance according modified acmg mt-cyb associated leigh syndrome however patient harbored typical clinical feature leigh syndrome existing clinical data low-level heteroplasmy m.15272a could perfectly connected another patient harboured mt-co3 m.9984g chrna4 c.988g variant m.9984g reported patient suspected reclassified uncertain significance wong chrna4 assosited nocturnal frontal lobe epilepsy seizure main presentation patient provide definitive evidence case coexistence mutation ndna mtdna reported previous study however lack functional data confused digenic mechanism relationship ndna mtdna determined observing attributing phenotype krt10 mt-nd6 mt-nd1/mt-nd4 opa1 mt-nd1/mt-nd4 rtn4ip1 nd4 tmem126a single case could easily distinguish contribution two gene particularly causative gene similar patient observing co-segregation phenomenon calculating minor allele frequency variant prevalence disease study explored digenic mechanism defined contribution trmu ears2 heterozygous variant clinical manifestation disease caused m.14674 currently identify recurrence similarly affected unrelated patient study required determine likely clinical significance kerr found whole-exome sequencing provided second diagnosis two patient already pathogenic variant mtdna notably many variant purported causal disease may case unknown significance benign polymorphism recently whole-genome sequencing recommended early diagnosis patient local secondary tertiary care centre invasive test muscle biopsy present whole genomic sequencing easy use clinical diagnosis due massive amount data yield difficult select candidate variant interpret disease-causing role combination ndna mtdna sequencing alternative suspected patient study several limitation preliminary study overall cohort followed consistently variant unknown significance ndna mtdna gene needed test functional study verify finding highlighted importance dual genomic sequencing pediatric patient widespread use whole genome sequencing combination biochemical testing muscle histology study correctly molecular diagnosis would definitive next follow-up case data reanalysis based dual genomic sequencing combined transcriptome sequencing could significantly improve predictive probability identify underlying pathogenic gene conclusion study identified six patient dual genomic variant mtdna ndna demonstrated variant non-mitochondria-related ndna variant unknown significance patient high mdc score mdc could guide implementation dual genomic sequencing routine diagnostics esipecially patient assessed possibly mitochondrial disorder probably mitochondrial disorder dual genomic sequencing provided comprehensive research strategy identifiying patient dual genomic variant informing risk genetic transmission